BillionToOne reports Q4 EPS 11c, consensus 17c

Reports Q4 revenue $96.05M, consensus $87.2M. “2025 demonstrated how the compounding power of a differentiated technology platform, category-defining products, and disciplined execution can produce an extraordinary outcome,” said Oguzhan Atay, co-Founder and CEO of BillionToOne (BLLN). “With new prenatal and oncology products already launched, expanding payer coverage, and a growing base of providers choosing our tests, we are executing to solve the hardest problems in healthcare and give patients the answers they need. Entering 2026, we believe we are still in the earliest chapters of what is possible, and remain confident that our smNGS platform will continue to unlock diagnostic capabilities that transform patient lives one molecule at a time.”